Abeona Therapeutics (ABEO) Net Cash Flow (2011 - 2026)

Abeona Therapeutics' Net Cash Flow history runs 16 years deep, the most recent figure standing at -$17.1 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 129.93% year-over-year to -$17.1 million; the TTM figure through Mar 2026 stood at $45.1 million (up 2880.52% YoY), while the FY2025 annual figure was $54.7 million, up 516.19% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$17.1 million, down from -$4.8 million in the prior quarter.
• The five-year high for Net Cash Flow was $147.6 million in Q2 2025, with the low at -$80.7 million in Q3 2025.
• The 5-year median for Net Cash Flow is -$1.5 million (2023), against an average of $1.5 million.
• Peak annual rise in Net Cash Flow reached 991.78% in 2024, while the deepest fall reached 1135.96% in 2024.
• Abeona Therapeutics' Net Cash Flow stood at $3.5 million in 2022, then surged by 180.17% to $9.8 million in 2023, then declined by 21.82% to $7.6 million in 2024, then tumbled by 162.7% to -$4.8 million in 2025, then sank by 256.59% to -$17.1 million in 2026.
• Business Quant data shows ABEO's Net Cash Flow at -$17.1 million in Q1 2026, -$4.8 million in Q4 2025, and -$80.7 million in Q3 2025.